SCHEMBL652035

SCHEMBL652035

COc1ccc(C(=O)CCC(=O)c2ccc3c(c2)OCCO3)cc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 12/20 0.78
WNT3A P56704 8/20 0.78
NPC1 O15118 3/20 0.71
MAPT P10636 2/20 0.71
ALDH1A1 P00352 2/20 0.71
LMNA P02545 1/20 0.71
PKM P14618 2/20 0.67
HPGD P15428 1/20 0.67
TSHR P16473 1/20 0.67
ATM Q13315 1/20 0.61
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
TP53 P04637 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15979976 0.91 CTNNB1 (0.78) CTNNB1WNT3ANPC1MAPTALDH1A1
SCHEMBL30440765 0.88 CTNNB1 (1.00) CTNNB1WNT3ANPC1PKMHPGD
SCHEMBL15969450 0.88 CTNNB1 (1.00) CTNNB1WNT3ANPC1PKMHPGD
SCHEMBL653025 0.86 PKM (0.87) CTNNB1WNT3AALDH1A1PKMHPGD
SCHEMBL15979884 0.84 NPC1 (0.59) CTNNB1WNT3ANPC1MAPTALDH1A1
SCHEMBL4825307 0.84 RAB9A (0.64) CTNNB1WNT3ANPC1MAPTALDH1A1
SCHEMBL10027736 0.84 CTNNB1 (1.00) CTNNB1WNT3ANPC1ALDH1A1PKM
SCHEMBL26624014 0.83 KMT2A (0.72) CTNNB1WNT3ANPC1MAPTALDH1A1
SCHEMBL15969541 0.83 CTNNB1 (0.73) CTNNB1WNT3ANPC1MAPTALDH1A1
SCHEMBL15979764 0.83 CTNNB1 (0.60) CTNNB1WNT3ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-02-23 US disclosed
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2022-03-24 US disclosed
EP-3915367-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS BioSplice Therapeutics, Inc. (US) 2021-12-01 EP disclosed
EP-3915367-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS BioSplice Therapeutics, Inc. (US) 2021-12-01 EP disclosed
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2021-11-18 US disclosed
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2021-11-18 US disclosed
US-8629176-B1 β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators SAMUMED, LLC (US) 2014-01-14 US disclosed
US-8629176-B1 β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators SAMUMED, LLC (US) 2014-01-14 US disclosed
US-20140005228-A1 B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS SAMUMED, LLC (US) 2014-01-02 US disclosed
US-8609717-B2 β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2013-12-17 US disclosed
EP-2605652-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS Samumed, LLC (US) 2013-06-26 EP disclosed
WO-2012024404-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 WO disclosed
WO-2012024404-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 WO disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885NPC1 4073/4885
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885NPC1 2194/4885
US-20140005228-A1 B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3B, WNT3A, GSK3A CTNNB1 6/4885WNT3A 2/4885NPC1 2588/4885
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles DGKG, DGKA, DNER CTNNB1 1475/4885WNT3A 1983/4885NPC1 3947/4885
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885NPC1 1560/4885
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WNT1, CTNNA1, WNT3A CTNNB1 6/4885WNT3A 3/4885NPC1 2200/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CTNNB1 5/4885WNT3A 4/4885NPC1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.